Vanda Pharmaceuticals
VNDA
110 hedge funds and large institutions have $622M invested in Vanda Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 38 increasing their positions, 37 reducing their positions, and 23 closing their positions.
434% more call options, than puts
Call options by funds: $40.9M | Put options by funds: $7.66M
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
9% more capital invested
Capital invested by funds: $571M → $622M (+$50.8M)
4% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 23
3% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 37
1% more funds holding
Funds holding: 109 → 110 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Paulson & Co
New York
|
+$24.1M |
| 2 |
SCA
Signpost Capital Advisors
New York
|
+$22.5M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$22.3M |
| 4 |
KCM
Kingdon Capital Management
New York
|
+$7.81M |
| 5 |
DM
Deerfield Management
New York
|
+$7.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$19.9M |
| 2 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$9.86M |
| 3 |
AGA
Altrinsic Global Advisors
Stamford,
Connecticut
|
-$5.69M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$3.66M |
| 5 |
TAM
THB Asset Management
Norwalk,
Connecticut
|
-$3.38M |
VNDA Hedge Fund Activity: Q2 2014 in Review
110 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q2 2014, worth a combined $622M — up 8.9% from $571M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new VNDA positions and 23 closed out — a net gain of 1 holder — while 38 added to existing stakes and 37 trimmed.
The largest buyer was Paulson & Co, adding an estimated $24.1M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $19.9M sold.
- 110 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q2 2014, up from 109 in Q1 2014.
- Funds reported $622M of Vanda Pharmaceuticals stock for Q2 2014, up 8.9% quarter-over-quarter.
- 24 funds opened new Vanda Pharmaceuticals positions in Q2 2014 and 23 closed out, a net change of +1 holder.
- The largest Vanda Pharmaceuticals buyer in Q2 2014 was Paulson & Co, an estimated $24.1M added.
- The largest Vanda Pharmaceuticals seller in Q2 2014 was Consonance Capital Management, an estimated $19.9M sold.
Based on aggregated 13F filings for Q2 2014.